Results · Apr-Jun 2026
Jenburkt Pharmaceuticals Q1 FY27 results
Sales was flat at ₹35.5 crore against Apr-Jun 2025.
Operating profit fell 33% to ₹6 crore, an operating margin of 17.0% (down 8.2 points from a year ago).
Net profit fell 24% to ₹5.9 crore from ₹7.8 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −20%, net profit −46%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 35.5 | 35.5 | −0% |
| Operating profit (EBITDA) | 6.0 | 9.0 | −33% |
| Operating margin | 17.0% | 25.2% | −8.2 pts |
| Net profit | 5.9 | 7.8 | −24% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.